$351.94
▲ +0.3% Today
as of Aug 5, 16:56 ET
Last 30 days
Recent Press Releases & News
WST: Raising target price to $384.00
Is Stronger Q2 Results, Raised Outlook and Buybacks Altering The Investment Case For West Pharmaceutical Services (WST)?
West Pharmaceutical Services (WST) Raised Guidance, Is The Upside Already Priced In?
Overview
52-week range
$207
$331
100% of range
Avg surprise (last 2)
+20.4%
Avg reaction (last 2)
+9.7%
50% positive
Latest IV / EM
27%
EM ±4.5% · $350 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $1.92 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $1.92 | — | — | — | — | financials |
| Thu Jul 24, 2025 | Jun/2025 | $1.84 | $1.51 | +21.9% | — | +22.8% | earnings |
| Thu Apr 24, 2025 | Mar/2025 | $1.45 | $1.22 | +18.9% | — | -3.5% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $1.85 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $1.51 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $1.55 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $2.14 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $2.06 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $548M | — | $510M | $493M | $466M | — | $482M | $472M |
| Gross profit | $296M | — | $294M | $274M | $232M | — | $265M | $230M |
| Operating income | $177M | — | $168M | $154M | $107M | — | $161M | $126M |
| Net income | $139M | — | $140M | $132M | $90M | — | $136M | $111M |
| EPS (diluted) | $1.92 | — | $1.92 | $1.82 | $1.23 | — | $1.85 | $1.51 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $521M | $791M | $628M | $510M | $404M | $485M | $491M | $446M |
| Inventory | $453M | $444M | $438M | $421M | $389M | $377M | $401M | $419M |
| Total current assets | $1.83B | $1.98B | $1.82B | $1.68B | $1.46B | $1.54B | $1.55B | $1.48B |
| Total assets | $4.11B | $4.27B | $4.11B | $3.95B | $3.62B | $3.64B | $3.68B | $3.49B |
| Long-term debt | $203M | $203M | $203M | $203M | $203M | $203M | $203M | $73M |
| Total liabilities | $1.12B | $1.09B | $1.05B | $1.02B | $935M | $961M | $923M | $913M |
| Total equity | $2.99B | $3.18B | $3.05B | $2.93B | $2.68B | $2.68B | $2.75B | $2.58B |